Mesenchymal stem/stromal cells genetically engineered to produce vascular endothelial growth factor for revascularization in wound healing and ischemic conditions

Fernando A Fierro, Nataly Magner, Julie Beegle, Heather Dahlenburg, Jeannine Logan White, Ping Zhou, Karen Pepper, Brian Fury, Dane Philip Coleal-Bergum, Gerhard Bauer, William Gruenloh, Geralyn Annett, Christy Pifer, Jan Nolta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Mesenchymal stem/stromal cells (MSCs) may be able to improve ischemic conditions as they can actively seek out areas of low oxygen and secrete proangiogenic factors. In more severe trauma and chronic cases, however, cells alone may not be enough. Therefore, we have combined the stem cell and angiogenic factor approaches to make a more potent therapy. We developed an engineered stem cell therapy product designed to treat critical limb ischemia that could also be used in trauma-induced scarring and fibrosis where additional collateral blood flow is needed following damage to and blockage of the primary vessels. We used MSCs from normal human donor marrow and engineered them to produce high levels of the angiogenic factor vascular endothelial growth factor (VEGF). The MSC/VEGF product has been successfully developed and characterized using good manufacturing practice (GMP)-compliant methods, and we have completed experiments showing that MSC/VEGF significantly increased blood flow in the ischemic limb of immune deficient mice, compared to the saline controls in each study. We also performed safety studies demonstrating that the injected product does not cause harm and that the cells remain around the injection site for more than 1 month after hypoxic preconditioning. An on-demand formulation system for delivery of the product to clinical sites that lack cell processing facilities is in development.

Original languageEnglish (US)
JournalTransfusion
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Mesenchymal Stromal Cells
Wound Healing
Vascular Endothelial Growth Factor A
Angiogenesis Inducing Agents
Extremities
Stem Cell Factor
Wounds and Injuries
Cell- and Tissue-Based Therapy
Cicatrix
Fibrosis
Stem Cells
Ischemia
Bone Marrow
Oxygen
Safety
Injections

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

Mesenchymal stem/stromal cells genetically engineered to produce vascular endothelial growth factor for revascularization in wound healing and ischemic conditions. / Fierro, Fernando A; Magner, Nataly; Beegle, Julie; Dahlenburg, Heather; Logan White, Jeannine; Zhou, Ping; Pepper, Karen; Fury, Brian; Coleal-Bergum, Dane Philip; Bauer, Gerhard; Gruenloh, William; Annett, Geralyn; Pifer, Christy; Nolta, Jan.

In: Transfusion, 01.01.2018.

Research output: Contribution to journalArticle

Fierro, Fernando A ; Magner, Nataly ; Beegle, Julie ; Dahlenburg, Heather ; Logan White, Jeannine ; Zhou, Ping ; Pepper, Karen ; Fury, Brian ; Coleal-Bergum, Dane Philip ; Bauer, Gerhard ; Gruenloh, William ; Annett, Geralyn ; Pifer, Christy ; Nolta, Jan. / Mesenchymal stem/stromal cells genetically engineered to produce vascular endothelial growth factor for revascularization in wound healing and ischemic conditions. In: Transfusion. 2018.
@article{2bed466fc2194f9dadea034c2ffb91ce,
title = "Mesenchymal stem/stromal cells genetically engineered to produce vascular endothelial growth factor for revascularization in wound healing and ischemic conditions",
abstract = "Mesenchymal stem/stromal cells (MSCs) may be able to improve ischemic conditions as they can actively seek out areas of low oxygen and secrete proangiogenic factors. In more severe trauma and chronic cases, however, cells alone may not be enough. Therefore, we have combined the stem cell and angiogenic factor approaches to make a more potent therapy. We developed an engineered stem cell therapy product designed to treat critical limb ischemia that could also be used in trauma-induced scarring and fibrosis where additional collateral blood flow is needed following damage to and blockage of the primary vessels. We used MSCs from normal human donor marrow and engineered them to produce high levels of the angiogenic factor vascular endothelial growth factor (VEGF). The MSC/VEGF product has been successfully developed and characterized using good manufacturing practice (GMP)-compliant methods, and we have completed experiments showing that MSC/VEGF significantly increased blood flow in the ischemic limb of immune deficient mice, compared to the saline controls in each study. We also performed safety studies demonstrating that the injected product does not cause harm and that the cells remain around the injection site for more than 1 month after hypoxic preconditioning. An on-demand formulation system for delivery of the product to clinical sites that lack cell processing facilities is in development.",
author = "Fierro, {Fernando A} and Nataly Magner and Julie Beegle and Heather Dahlenburg and {Logan White}, Jeannine and Ping Zhou and Karen Pepper and Brian Fury and Coleal-Bergum, {Dane Philip} and Gerhard Bauer and William Gruenloh and Geralyn Annett and Christy Pifer and Jan Nolta",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/trf.14914",
language = "English (US)",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Mesenchymal stem/stromal cells genetically engineered to produce vascular endothelial growth factor for revascularization in wound healing and ischemic conditions

AU - Fierro, Fernando A

AU - Magner, Nataly

AU - Beegle, Julie

AU - Dahlenburg, Heather

AU - Logan White, Jeannine

AU - Zhou, Ping

AU - Pepper, Karen

AU - Fury, Brian

AU - Coleal-Bergum, Dane Philip

AU - Bauer, Gerhard

AU - Gruenloh, William

AU - Annett, Geralyn

AU - Pifer, Christy

AU - Nolta, Jan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Mesenchymal stem/stromal cells (MSCs) may be able to improve ischemic conditions as they can actively seek out areas of low oxygen and secrete proangiogenic factors. In more severe trauma and chronic cases, however, cells alone may not be enough. Therefore, we have combined the stem cell and angiogenic factor approaches to make a more potent therapy. We developed an engineered stem cell therapy product designed to treat critical limb ischemia that could also be used in trauma-induced scarring and fibrosis where additional collateral blood flow is needed following damage to and blockage of the primary vessels. We used MSCs from normal human donor marrow and engineered them to produce high levels of the angiogenic factor vascular endothelial growth factor (VEGF). The MSC/VEGF product has been successfully developed and characterized using good manufacturing practice (GMP)-compliant methods, and we have completed experiments showing that MSC/VEGF significantly increased blood flow in the ischemic limb of immune deficient mice, compared to the saline controls in each study. We also performed safety studies demonstrating that the injected product does not cause harm and that the cells remain around the injection site for more than 1 month after hypoxic preconditioning. An on-demand formulation system for delivery of the product to clinical sites that lack cell processing facilities is in development.

AB - Mesenchymal stem/stromal cells (MSCs) may be able to improve ischemic conditions as they can actively seek out areas of low oxygen and secrete proangiogenic factors. In more severe trauma and chronic cases, however, cells alone may not be enough. Therefore, we have combined the stem cell and angiogenic factor approaches to make a more potent therapy. We developed an engineered stem cell therapy product designed to treat critical limb ischemia that could also be used in trauma-induced scarring and fibrosis where additional collateral blood flow is needed following damage to and blockage of the primary vessels. We used MSCs from normal human donor marrow and engineered them to produce high levels of the angiogenic factor vascular endothelial growth factor (VEGF). The MSC/VEGF product has been successfully developed and characterized using good manufacturing practice (GMP)-compliant methods, and we have completed experiments showing that MSC/VEGF significantly increased blood flow in the ischemic limb of immune deficient mice, compared to the saline controls in each study. We also performed safety studies demonstrating that the injected product does not cause harm and that the cells remain around the injection site for more than 1 month after hypoxic preconditioning. An on-demand formulation system for delivery of the product to clinical sites that lack cell processing facilities is in development.

UR - http://www.scopus.com/inward/record.url?scp=85055941197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055941197&partnerID=8YFLogxK

U2 - 10.1111/trf.14914

DO - 10.1111/trf.14914

M3 - Article

C2 - 30383901

AN - SCOPUS:85055941197

JO - Transfusion

JF - Transfusion

SN - 0041-1132

ER -